Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing

Whitehead, Timothy A; Chevalier, Aaron; Song, Yifan; Dreyfus, Cyrille; Fleishman, Sarel J; De Mattos, Cecilia; Myers, Chris A; Kamisetty, Hetunandan; Blair, Patrick; Wilson, Ian A; Baker, David
June 2012
Nature Biotechnology;Jun2012, Vol. 30 Issue 6, p543
Academic Journal
We show that comprehensive sequence-function maps obtained by deep sequencing can be used to reprogram interaction specificity and to leapfrog over bottlenecks in affinity maturation by combining many individually small contributions not detectable in conventional approaches. We use this approach to optimize two computationally designed inhibitors against H1N1 influenza hemagglutinin and, in both cases, obtain variants with subnanomolar binding affinity. The most potent of these, a 51-residue protein, is broadly cross-reactive against all influenza group 1 hemagglutinins, including human H2, and neutralizes H1N1 viruses with a potency that rivals that of several human monoclonal antibodies, demonstrating that computational design followed by comprehensive energy landscape mapping can generate proteins with potential therapeutic utility.


Related Articles

  • Evaluation of neutralizing efficacy of monoclonal antibodies specific for 2009 pandemic H1N1 influenza A virus in vitro and in vivo. Chen, Jianjun; Yan, Bin; Chen, Quanjiao; Yao, Yanfeng; Wang, Huadong; Liu, Qian; Zhang, Shaoqiong; Wang, Hanzhong; Chen, Ze // Archives of Virology;Mar2014, Vol. 159 Issue 3, p471 

    Pandemic influenza A virus (H1N1) 2009 poses a serious public-health challenge worldwide. To characterize the neutralizing epitopes of this virus, we generated a panel of eight monoclonal antibodies (mAbs) against the HA of the A/California/07/2009 virus. The antibodies were specific for the...

  • Antivirals: New clues for flu vaccine design. Crunkhorn, Sarah // Nature Reviews Drug Discovery;Oct2011, Vol. 10 Issue 10, p733 

    The article focuses on the medical studies about the significance of human antibodies for the development of vaccines against influenza. It highlights the study conducted by Ekiert and colleagues which examines the development of stable monoclonal antibody (mAb)-producing human memory B cells...

  • Isolation of a High Affinity Neutralizing Monoclonal Antibody against 2009 Pandemic H1N1 Virus That Binds at the 'Sa' Antigenic Site. Shembekar, Nachiket; Aditya Mallajosyula, Vamsee V.; Mishra, Arpita; Yeolekar, Leena; Dhere, Rajeev; Kapre, Subhash; Varadarajan, Raghavan; Gupta, Satish Kumar // PLoS ONE;Jan2013, Vol. 8 Issue 1, Special section p1 

    Influenza virus evades host immunity through antigenic drift and shift, and continues to circulate in the human population causing periodic outbreaks including the recent 2009 pandemic. A large segment of the population was potentially susceptible to this novel strain of virus. Historically,...

  • Chinese herbs for flu treatment. Elliott, William T. // Neurology Alert;Oct2011 Clinical Briefs, p2 

    The article discusses research on H1N1 influenza treatment, referencing a study published in the "Annals of Internal Medicine," which concludes that oseltamivir and Chinese herbs called maxingshigan-yinqiaosan, alone or in combination, decrease time-to-fever resolution in H1N1 influenza patients.

  • CME Questions.  // Infectious Disease Alert;Dec2009, Vol. 29 Issue 3, p34 

    A quiz concerning the treatment of H1N1 influenza virus infection is presented.

  • Correction: Oseltamivir Compared With Chinese Traditional Therapy.  // Annals of Internal Medicine;1/3/2012, Vol. 156 Issue 1, p71 

    A correction to the article "Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: A randomized trial" that was published in the 2011 issue is presented.

  • Timing for influenza A (H1N1) therapy remains up for debate.  // Infectious Diseases in Children;Dec2009, Vol. 22 Issue 12, p25 

    The article reports on an ongoing concern among clinicians over the recommended 48-hour window for initiating antivial therapy for the treatment of influenza A (H1N1) virus.

  • TESTING FOR H1N1. Degenstein, Tracy // Clinical Advisor;Feb2010, Vol. 13 Issue 2, p83 

    The article provides an answer to a question on whether to start a patient with a fever and dry cough on Tamiflu without testing for the H1N1 influenza.

  • Oseltamivir.  // Reactions Weekly;9/24/2011, Issue 1370, p30 

    The article describes the case of a 46-year-old woman who developed angioedema while being treated with oseltamivir for H1N1 influenza.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics